ERBB2 and triple-negative breast carcinoma: Approximately 10–15% of all breast cancers are defined as triple-negative breast cancers (TNBC), with known cell surface molecular markers (estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2)) not being highly expressed.